中文 | English
Return
Total: 220 , 1/22
Show Home Prev Next End page: GO
MeSH:(Hepatitis C, Chronic/drug therapy*)

1.Mechanism and clinical significance of HBV reactivation after anti-HCV therapy.

Wan Jia ZENG ; Lin GAO ; Yi Wei XU ; Xiang Mei CHEN ; Fu Sheng WANG ; Feng Min LU

Chinese Journal of Hepatology 2022;30(9):997-1001

2.Advances in new antivirals for chronic hepatitis B.

Yanhua TANG ; Hongyan LIANG ; Ge ZENG ; Sheng SHEN ; Jian SUN

Chinese Medical Journal 2022;135(5):571-583

3.Clinical Implications of Chemokines in Acute and Chronic Hepatitis C Virus Infection.

Wonseok KANG ; Eui Cheol SHIN

Yonsei Medical Journal 2011;52(6):871-878

7.Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection

Shinya SATO ; Kei MORIYA ; Masanori FURUKAWA ; Soichiro SAIKAWA ; Tadashi NAMISAKI ; Mitsuteru KITADE ; Hideto KAWARATANI ; Kosuke KAJI ; Hiroaki TAKAYA ; Naotaka SHIMOZATO ; Yasuhiko SAWADA ; Kenichiro SEKI ; Koh KITAGAWA ; Takemi AKAHANE ; Akira MITORO ; Yasushi OKURA ; Junichi YAMAO ; Hitoshi YOSHIJI

Clinical and Molecular Hepatology 2019;25(1):65-73

8.Antiviral therapy for "difficult-to-treat" hepatitis C virus-infected patients.

Tatsuo KANDA ; Osamu YOKOSUKA ; Masao OMATA

Chinese Medical Journal 2013;126(23):4568-4574

9.Consensus on management of drug-drug interaction with direct-acting antiviral agents in chronic hepatitis C.

Chinese Journal of Hepatology 2018;26(7):481-488

10.Occurrence and recurrence of hepatitis C-related hepatocellular carcinoma after direct antiviral treatment.

Yu Qing YANG ; Xiao Yuan XU

Chinese Journal of Hepatology 2022;30(1):103-106

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 220 , 1/22 Show Home Prev Next End page: GO